Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

The fourth-quarter 2024 earnings season will kick off this week, with banking sector players due to report numbers. The ...

Three Australian fund managers who delivered annualised double-digit returns over the past 10 years share their views on what ...

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy. The strategy helps investors gain ...

According to the latest Earnings Trends report, total S&P 500 earnings are expected to be up 7.4% from the year-ago period on ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

Across two phase 3 trials, Zepbound reduced OSA episodes in both participants using positive airway pressure (PAP), the standard of care for moderate to severe OSA, which involves wearing a mask ...